IBR854 plus pazopanib vs pazopanib for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new combination therapy (IBR854 plus pazopanib) against pazopanib alone for people with advanced clear cell kidney cancer who haven't had prior treatment. It aims to see if the combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced clear cell kidney cancer that cannot be removed with surgery.
- You have not received any prior cancer treatment for advanced disease.
- You are in generally good health (able to do daily activities with little or no help).
- Your cancer can be measured on scans (at least one tumor that can be tracked).
- You have adequate blood counts, liver and kidney function, and no active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial is testing a new drug combination for people with advanced kidney cancer. The main drug, BL-B01D1, is given together with a targeted therapy (TKI) and sometimes also with an immunotherapy drug (pembrolizumab). The goal is to see if this combination can shrink tumors or slow cancer growth.
This Phase 3 trial studies how well pazopanib works, and whether adding abexinostat can improve outcomes, for advanced kidney cancer that cannot be removed by surgery or has spread. You may qualify if you have clear cell renal cell carcinoma and have not already had certain targeted kidney-cancer medicines.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug (BMS-986506) for people with advanced kidney cancer (clear cell renal cell carcinoma). It aims to see if the drug is safe and effective. Depending on the part of the study, participants may have had prior treatments or be newly diagnosed.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
Hear when a new Renal Cell Carcinoma (RCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.